NCT07721259
A Vaccine (STEMVAC) for Improving Survival in Patients With Triple-Negative Breast Cancer and Moderate or Extensive Residual Cancer Burden
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 3 versions: 3 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date pushed from Nov 1, 2026 to Dec 15, 2026
- Site details revised
Notable Start date: Sep 30, 2026 to Nov 1, 2026 Show 4 more changesShow less
- Eligibility criteria expanded, about 34 words
- Interventions: Biospecimen Collection (Procedure), CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine (Biological), Recombinant… to Biospecimen Collection (Procedure), CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine (Biological), Recombinant…
- Secondary endpoints: details revised at 3 of 3 entries
- Site details revised
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Secondary (3)
Arms and interventions
Patients receive STEMVAC with GM-CSF ID every 3 weeks for 3 doses. Patients then receive booster vaccines ID 9 weeks after vaccine 3 and 18 weeks after booster 1. Patients also undergo collection of blood samples throughout the trial.
Patients receive GM-CSF ID every 3 weeks for 3 doses. Patients then receive booster vaccines ID 9 weeks after vaccine 3 and 18 weeks after booster 1. Patients also undergo collection of blood samples throughout the trial.
Biologicals: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Drugs: Recombinant Granulocyte-Macrophage Colony-Stimulating Factor
Procedures: Biospecimen Collection
Sites
1 site in 1 country
- Fred Hutch/University of Washington Cancer ConsortiumSeattle, Washington, United States